Altria Group, Inc.

MO ·Consumer Defensive, Tobacco, United States

Altria Group, Inc. (MO)

Overview

Altria Group is one of the largest producers and marketers of tobacco, cigarettes, and related products in the United States, headquartered in Richmond, Virginia. The company sits in the consumer staples sector (tobacco industry) and is the domestic parent of the former Philip Morris USA business, best known for the Marlboro cigarette brand. Altria is a large but lean organization — it reported roughly $23.3 billion in net revenues for full-year 2025, generated with a relatively small direct workforce of around 5,900 employees, reflecting a business model built on manufacturing efficiency, brand strength, and heavy reliance on a distribution network of roughly 300,000 retail outlets across all 50 states. Altria is separate from Philip Morris International (PMI), the two having split in 2008 to divide U.S. and international tobacco operations.

What They Do & How They Make Money

Altria makes money primarily by manufacturing and selling nicotine and tobacco products to adult consumers in the U.S., collecting revenue on volume and price across a portfolio of premium and value brands. Its core business remains combustible cigarettes — chiefly Marlboro, which commands a dominant share of the U.S. cigarette market — sold through wholesalers and retailers rather than directly to consumers. Because U.S. cigarette volumes have declined for decades due to health awareness, regulation, and taxation, Altria has increasingly relied on pricing power (raising prices faster than volume declines) to sustain revenue and profit, along with cost discipline. The company also earns money from smokeless and oral nicotine products (moist snuff and nicotine pouches), which carry different regulatory and growth profiles than cigarettes, and it holds investment stakes in other companies — including an equity interest in global brewer Anheuser-Busch InBev (from the 2016 SABMiller deal) and a large stake in cannabis company Cronos Group — that contribute to earnings through equity income and dividends rather than product sales. Altria returns substantial cash to shareholders via dividends, historically prioritizing a high and growing payout as its core cigarette business generates more cash than it needs to reinvest.

Business Segments

Altria organizes its reporting into three primary segments per its 10-K filings:

Smokeable Products — the company's largest segment by far, covering cigarettes (Marlboro and other brands) and machine-made large cigars (Black & Mild). It generated about $20.5 billion in net revenue and $11.1 billion in operating income in 2025, underscoring how dominant combustibles remain to overall profitability despite long-term volume decline.
Oral Tobacco Products — moist smokeless tobacco (Copenhagen, Skoal) and oral nicotine pouches (on!). This segment generated about $2.8 billion in revenue and $1.8 billion in operating income in 2025, and has been a rare growth pocket as pouches gain adult consumer adoption.
E-Vapor / All Other — anchored by NJOY, the FDA-authorized e-vapor brand Altria acquired after its earlier, largely written-off investment in JUUL Labs. This segment remains small and unprofitable, posting an operating loss of roughly $2.3 billion in 2025 (including impairment and related charges), reflecting the difficulty and regulatory friction Altria has faced trying to build a credible vapor business following the JUUL setback.

Beyond these three operating segments, Altria's equity stakes in AB InBev (about 8.2%) and Cronos Group (roughly 41%) are reported separately as investments in equity securities rather than consolidated segments, but they materially affect reported net income.

Competitors

Combustible cigarettes: Reynolds American (owned by British American Tobacco), the maker of Newport and Camel, is Altria's chief direct U.S. competitor; ITG Brands (owner of Winston and Kool, a Japan Tobacco affiliate) is a smaller rival.
Global tobacco (indirect, given geographic separation): Philip Morris International, Altria's former parent-company sibling, competes globally with combustible and reduced-risk products (like IQOS) but generally not head-to-head with Altria in the U.S. market due to a long-standing agreement between the companies, though PMI's planned re-entry into the U.S. IQOS market and its 2025 pursuits create renewed overlap.
Oral/smokeless and nicotine pouches: Swedish Match (owned by PMI, maker of ZYN) is Altria's most direct and fast-growing rival in nicotine pouches, alongside British American Tobacco's Velo brand.
E-vapor/vaping: Vuse (British American Tobacco) is the U.S. vaping category leader that NJOY competes against, along with a large gray market of imported disposable vapes.

Competitive Position

Altria's core competitive advantage is the enduring strength of Marlboro, which retains a commanding share of the declining but still large U.S. cigarette market, giving Altria significant pricing power and cash-generation capability even as unit volumes shrink a few percentage points per year. This scale and brand loyalty, combined with an efficient low-headcount operating model, let Altria consistently produce high margins and fund a large dividend that has made it a favorite among income-focused investors. The company's key risks are structural and regulatory: continued long-term decline in cigarette consumption, potential FDA action on menthol cigarettes or nicotine yield caps, rising illicit and flavored disposable vape competition that undercuts NJOY, state and federal excise tax increases, litigation exposure tied to tobacco's health effects, and the cautionary example of its roughly $11 billion in cumulative JUUL-related write-offs, which illustrate the difficulty Altria has had diversifying beyond its traditional combustible base. Its equity stakes in AB InBev and Cronos provide some diversification and optionality but have also been volatile and, in Cronos's case, a source of investment losses. Overall, Altria is best understood as a high-margin, slow-growth, cash-return business defending a dominant but structurally shrinking category while trying — with mixed success so far — to build credible positions in smoke-free alternatives.